176 related articles for article (PubMed ID: 9890489)
21. In vivo and in vitro expression of somatostatin receptors in two human thymomas with similar clinical presentation and different histological features.
Ferone D; Kwekkeboom DJ; Pivonello R; Bogers ADColao A; Lamberts SW; van Hagen PM; Hofland LJ
J Endocrinol Invest; 2001; 24(7):522-8. PubMed ID: 11508787
[TBL] [Abstract][Full Text] [Related]
22. Utility of ¹¹¹indium-pentetreotide scintigraphy in patients with neuroendocrine tumors.
Shaverdian N; Pinchot SN; Zarebczan B; Gillis HC; Schiro A; Chen H
Ann Surg Oncol; 2013 Feb; 20(2):640-5. PubMed ID: 22941169
[TBL] [Abstract][Full Text] [Related]
23. Visualization of fibrous dysplasia during somatostatin receptor scintigraphy.
Chen CC; Czerwiec FS; Feuillan PP
J Nucl Med; 1998 Feb; 39(2):238-40. PubMed ID: 9476926
[TBL] [Abstract][Full Text] [Related]
24. [Somatostatin receptor status in non-medullary thyroid carcinoma].
Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A
Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777
[TBL] [Abstract][Full Text] [Related]
25. Scintigraphic assessment of pituitary adenomas and several diseases by indium-111-pentetreotide.
Tumiati MN; Facchi E; Gatti C; Bossi A; Longari V
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):98-100. PubMed ID: 9002761
[TBL] [Abstract][Full Text] [Related]
26. Radiolabelled somatostatin analogue scintigraphy in oncology.
O'Byrne KJ; Carney DN
Anticancer Drugs; 1996 Jan; 7 Suppl 1():33-44. PubMed ID: 8822083
[TBL] [Abstract][Full Text] [Related]
27. Multiple endocrine neoplastic-associated thymic carcinoid tumour in close relatives: octreotide scan as a new diagnostic and follow-up modality. Two case reports.
Satta J; Ahonen A; Parkkila S; Leinonen L; Apaja-Sarkkinen M; Lepojärvi M; Juvonen T
Scand Cardiovasc J; 1999; 33(1):49-53. PubMed ID: 10093860
[TBL] [Abstract][Full Text] [Related]
28. Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2 expression: new prognostic factors for malignant well-differentiated endocrine tumors.
Asnacios A; Courbon F; Rochaix P; Bauvin E; Cances-Lauwers V; Susini C; Schulz S; Boneu A; Guimbaud R; Buscail L
J Clin Oncol; 2008 Feb; 26(6):963-70. PubMed ID: 18281671
[TBL] [Abstract][Full Text] [Related]
29. Somatostatin receptor imaging in patients with sarcoidosis.
Kwekkeboom DJ; Krenning EP; Kho GS; Breeman WA; Van Hagen PM
Eur J Nucl Med; 1998 Sep; 25(9):1284-92. PubMed ID: 9724378
[TBL] [Abstract][Full Text] [Related]
30. [Gammagraphy of somatostatin receptors in an ACTH secreting thymic carcinoid].
Banzo J; Razola P; Prats E; Freile E; Benito JL; García López F; García Tirado J; Abós MD
Rev Esp Med Nucl; 1999; 18(2):99-103. PubMed ID: 10352322
[TBL] [Abstract][Full Text] [Related]
31. Somatostatin receptor scintigraphy of a patient with a giant invasive prolactinoma.
Meyer P; Bohnen NI; Barkan AL; Shapiro B
Nuklearmedizin; 1999; 38(2):66-7. PubMed ID: 10100234
[TBL] [Abstract][Full Text] [Related]
32. Incidental appendix carcinoid. Value of somatostatin receptor imaging.
Hoegerle S; Nitzsche EU; Stumpf A; Simon GH; Otte A; Schwarzkopf G; Moser E
Clin Nucl Med; 1997 Jul; 22(7):467-9. PubMed ID: 9227869
[TBL] [Abstract][Full Text] [Related]
33. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N
Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of the new TNM-staging system for thymic malignancies: impact on indication and survival.
Ried M; Eicher MM; Neu R; Sziklavari Z; Hofmann HS
World J Surg Oncol; 2017 Dec; 15(1):214. PubMed ID: 29197400
[TBL] [Abstract][Full Text] [Related]
35. 111In-octreotide scintigraphy in small cell lung cancer.
Semprebene A; Ferraironi A; Franciotti G; Venturo I; Giunta S; Lopez M; Maini CL
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):108-10. PubMed ID: 9002764
[TBL] [Abstract][Full Text] [Related]
36. Imaging of somatostatin receptors by indium-111-pentetreotide correlates with quantitative determination of somatostatin receptor type 2 gene expression in neuroblastoma tumors.
Briganti V; Sestini R; Orlando C; Bernini G; La Cava G; Tamburini A; Raggi CC; Serio M; Maggi M
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2385-91. PubMed ID: 9815638
[TBL] [Abstract][Full Text] [Related]
37. Studies on radiolabeled somatostatin analogues in rats and in patients.
Breeman WA; Bakker WH; De Jong M; Hofland LJ; Kwekkeboom DJ; Kooij PP; Visser TJ; Krenning EP
Q J Nucl Med; 1996 Sep; 40(3):209-20. PubMed ID: 8961800
[TBL] [Abstract][Full Text] [Related]
38. In vivo detection of malignant thymic masses by indium-111-DTPA-D-Phe1-octreotide scintigraphy.
Lastoria S; Vergara E; Palmieri G; Acampa W; Varrella P; Caracò C; Bianco RA; Muto P; Salvatore M
J Nucl Med; 1998 Apr; 39(4):634-9. PubMed ID: 9544670
[TBL] [Abstract][Full Text] [Related]
39. Invasive thymomas: diagnosis and evaluation by computed tomography.
Zerhouni EA; Scott WW; Baker RR; Wharam MD; Siegelman SS
J Comput Assist Tomogr; 1982 Feb; 6(1):92-100. PubMed ID: 7069019
[TBL] [Abstract][Full Text] [Related]
40. Comparison of octreotide scintigraphy and conventional imaging in medullary thyroid carcinoma.
Baudin E; Lumbroso J; Schlumberger M; Leclere J; Giammarile F; Gardet P; Roche A; Travagli JP; Parmentier C
J Nucl Med; 1996 Jun; 37(6):912-6. PubMed ID: 8683310
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
